S100B and neoplasm: In this setting, trametinib suppressed both subcutaneous growth and plasma S100B levels (Figure 2C-D and Supplemental Figure 3B) and extended the time for the mice to achieve a tumor size that required ethical sacrifice (Figure 2E).